AI healthcare company Presagen will be presenting results of three new international clinical studies at the prestigious American Society for Reproductive Medicine (ASRM) Annual Meeting in October 2022, in Anaheim, California. These studies provide further clinical evidence of the benefits of Presagen’s Life Whisperer suite of AI products to support IVF and fertility treatment. The aim is to improve outcomes for patients, including reducing the time and cost to achieve a successful IVF outcome.
The studies were conducted with clinics across the globe in the USA, SE Asia, and Australia. They provide further clinical validation of Life Whisperer’s embryo quality assessment tools, and present a new product in development which uses AI to assess the quality of human eggs, or oocytes, prior to IVF or cryopreservation.
Life Whisperer currently uses Artificial Intelligence to assess images of IVF patients’ embryos . Life Whisperer Viability AI assesses how likely an embryo is to lead to a pregnancy, and Life Whisperer Genetics AI non-invasively assesses an embryo’s genetic integrity (euploidy). Life Whisperer is currently authorized for sale in over 40 countries worldwide.
Results of the first study showed that combining AI-based assessments of embryo viability and euploidy resulted in superior embryo selection, leading to pregnancy in a fewer number of embryo transfers compared to the viability assessment alone (using simulated cohort ranking methods).
Currently, embryo viability assessment is conducted using a visual grading approach which is highly variable among different embryologists. Embryo genetics is evaluated using pre-implantation genetic testing for aneuploidy (PGT-A). PGT-A is an invasive test that is costly and time-consuming, and has not shown significant improvement in patient outcomes.
Results of the second study showed that Life Whisperer Genetics AI was able to predict live birth outcome, further supporting use of the AI for embryo selection in IVF. The AI-based approach provides a low-cost, non-invasive and instant embryo euploidy assessment.
Life Whisperer’s new AI assessment, Life Whisperer Oocyte, will assess egg quality. It is currently under development with clinical partners, representing over 150 IVF clinics around the world, who are contributing data and clinical support via Presagen’s AI Open Projects global healthcare collaboration platform. Life Whisperer Oocytes AI is expected to be available for use in 2023.
Results of the third study showed that an AI can predict which eggs would develop into embryos after fertilization. The Life Whisperer Oocytes AI could potentially be used to help doctors and patients make better informed choices about additional IVF cycles and egg freezing, which is important given the high cost of these procedures and ongoing storage, and a patient’s reliance on their frozen eggs for future family building.
Other applications for the AI include informing the likelihood of success for donor egg batches, selecting the highest quality eggs for fertilization, and, importantly, providing reassurance of the likelihood of IVF success to the patient.
The titles and summary of the three posters are:
Combined use of Artificial Intelligence (AI) algorithms for evaluating embryo viability and embryo genetics improves selection of embryos leading to clinical pregnancy
Summary: Pre-selection of embryos using genetics AI improved subsequent ranking using viability AI, with fewer cycles needed to achieve pregnancy. Results suggest genetics AI may be used in a similar manner to PGT-A to pre-select embryos that are more likely to be euploid, followed by morphology-based selection for transfer.
Prediction of live birth using Artificial Intelligence (AI) algorithm developed to evaluate embryo genetic status from Day 5 images
Summary: A genetics AI for evaluating embryo images was predictive of live birth, suggesting it may be detecting morphological features correlated with genetic status that are also indicative of live birth outcome.
A non-invasive Artificial Intelligence (AI) algorithm can predict competence of denuded oocytes from images taken prior to intracytoplasmic sperm injection (ICSI)
Summary: A novel AI algorithm had high predictive power for assessing whether oocytes will develop into a usable blastocyst from single, static oocyte images, denuded prior to ICSI. Further, a UDC data cleansing technique was able to improve AI performance by identifying and removing cases where good quality oocytes were likely mislabeled as non-competent due to external factors beyond oocyte quality, such as male infertility.
Life Whisperer is a world-leader in the application of AI in IVF. The Life Whisperer Viability and Genetics AI-based embryo assessment tools are the first to be commercialized in a series of applications that encompass the complete IVF journey. Life Whisperer aims to improve IVF success rates at every point and, as a result, reduce time-to-pregnancy, making IVF more affordable and accessible to patients globally. Life Whisperer is being used in IVF clinics around the world.
Presagen is an AI healthcare company that is changing the way clinics, patients, and medical data from around the world are connected through AI. Its platform, The Social Network for Healthcare, connects clinics and patients globally, and enables collaboration and data sharing to create scalable AI healthcare products that are affordable and accessible for all. The decentralized network democratizes the creation of AI products, promotes collaboration through incentives, and protects data privacy and ownership. With a focus on improving Women’s Health outcomes globally, Presagen’s first product, Life Whisperer, is being used by IVF clinics globally to improve pregnancy outcomes for couples struggling with fertility. With a vision of creating the largest network of clinics, patients, and medical data from around the world, Presagen is driving the future of AI Enhanced Healthcare.